In a study (189) that included patients with unresectable advanced pancreatic cancer, substantial CD4+ and CD8+ T-cell infiltration was observed at 2 weeks after intratumoral injection of HF10; the findings suggested that this therapy may have stimulated an antitumor immune response. Here, CD8A is linked to pancreatic neoplasm.